Initiator Pharma is a pharmaceutical company, listed on Spotlight Stockmarket (Ticker INIT)). Initiator Pharma is targeting CNS Disorders with Significant Unmet Needs. Its' two proprietary products in Phase II clinical trials, IPED2015 and IP201 for Erectile Dysfunction. Both compounds constitute new treatments for the indication of erectile dysfunction (ED) of either organic or psychogenic origin, respectively – the inability of a man to achieve and maintain an erection and thus be able to complete sexual intercourse. Initiator Pharma's new treatment method with IPED2015 is intended to treat many patients with erectile dysfunction who are resistant to current treatment methods.